Analyst Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Aethlon Medical (AEMD – Research Report) and keeping the price target at $7.00.
Vernon Bernardino has given his Buy rating due to a combination of factors that highlight Aethlon Medical’s advancements in their oncology program. A significant milestone was achieved with the first treatment of a patient using their Hemopurifier device, which is designed to capture harmful elements such as viruses and cancer-promoting exosomes. The Hemopurifier’s initial results are promising, showing a substantial reduction of exosomes in plasma, which supports its potential effectiveness as a treatment option.
Furthermore, the ongoing study of the Hemopurifier’s safety and feasibility in patients who do not respond to anti-PD-1 antibody therapy has yielded positive preliminary outcomes. Despite challenges in patient enrollment, the successful treatment of the first patient without device-related issues marks a critical step forward. The continuation of this study in Australian clinical sites, with forthcoming data analysis, reinforces the confidence in Aethlon Medical’s innovative approach, thus warranting the Buy rating and a price target of $7.